Filtered By:
Condition: Atrial Fibrillation
Management: Insurance

This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 363 results found since Jan 2013.

Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use
Abstract Oral anticoagulation (OAC) with either new oral anticoagulants (NOACs) or Vitamin-K antagonists (VKAs) is recommended by guidelines for patients with atrial fibrillation (AF) and a moderate to high risk of stroke. Based on a claims-based data set the aim of this study was to quantify the stroke-risk dependent OAC utilization profile of German AF patients and possible causes of OAC under-use. Our claims-based data set was derived from two German statutory health insurance funds for the years 2007–2010. All prevalent AF-patients in the period 2007–2009 were included. The OAC-need in 2010 was assumed wh...
Source: Journal of Thrombosis and Thrombolysis - May 29, 2015 Category: Hematology Source Type: research

Geographic Clustering of Emergency Department Presentations for Atrial Fibrillation and Flutter in Alberta, Canada
ConclusionsThis population‐based study spanned 12 fiscal years and showed variations in the number of people presenting to EDs for AFF and the number of ED presentations for AFF over geography. The potential clusters identified may represent geographic areas with higher disease severity or a lower availability of non‐ED health services. The clusters are not all likely to have occurred by chance, and further investigation and intervention could occur to reduce ED presentations for AFF.
Source: Academic Emergency Medicine - July 1, 2015 Category: Emergency Medicine Authors: Rhonda J. Rosychuk, Hensley H. Mariathas, Michelle M. Graham, Brian R. Holroyd, Brian H. Rowe Tags: Original Contribution Source Type: research

Geographic Clustering of Emergency Department Presentations for Atrial Fibrillation and Flutter in Alberta, Canada.
CONCLUSIONS: This population-based study spanned 12 fiscal years and showed variations in the number of people presenting to EDs for AFF and the number of ED presentations for AFF over geography. The potential clusters identified may represent geographic areas with higher disease severity or a lower availability of non-ED health services. The clusters are not all likely to have occurred by chance, and further investigation and intervention could occur to reduce ED presentations for AFF. PMID: 26205400 [PubMed - as supplied by publisher]
Source: Accident and Emergency Nursing - July 23, 2015 Category: Emergency Medicine Authors: Rosychuk RJ, Mariathas HH, Graham MM, Holroyd BR, Rowe BH Tags: Acad Emerg Med Source Type: research

The Disconnect Between Novel Oral Anticoagulant Eligibility and Provincial Drug Coverage: An Albertan Anticoagulation Clinic Audit
Publication date: August 2015 Source:Canadian Journal of Cardiology, Volume 31, Issue 8 Author(s): Sandeep K. Dhillon, M. Sean McMurtry, Tammy J. Bungard Canadian practice guidelines for nonvalvular atrial fibrillation (NVAF) recommend that most patients receive a novel oral anticoagulant (NOAC) in preference to warfarin to prevent stroke, but not all patients have insurance that covers NOACs. The gap between optimal therapy and drug coverage is unknown. We retrospectively assessed eligibility for NOACs in patients with NVAF at our single-centre anticoagulation clinic and ascertained whether provincial drug coverage w...
Source: Canadian Journal of Cardiology - July 26, 2015 Category: Cardiology Source Type: research

Autism in the Son of a Woman with Mitochondrial Myopathy and Dysautonomia: A Case Report
Conclusion Given emerging evidence that mitochondrial dysfunction, particularly in the electron transport chain needed for cellular energy production, is an underlying pathophysiological mechanism for some varieties of ASD, clinicians should have a high index of suspicion for mitochondrial disease, especially when they encounter a patient with unusual neurological or constitutional symptoms. The prevalence of mitochondrial disease in ASD patients may be as high as five percent, which means that it is not the “zebra”[27] diagnosis that it might be in a non-ASD patient, where prevalence is about 0.01 percent.10 Reference...
Source: Innovations in Clinical Neuroscience - October 9, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Anxiety Disorders Asperger's syndrome Autism Behavioral and Cognitive Neurology Case Report Current Issue Intellectual Disability Neurologic Systems and Symptoms Pervasive Developmental Disorders ASD autism spectrum disorder dysauton Source Type: research

Neurologist ambulatory care, health care utilization, and costs in a large commercial dataset
Conclusion: Neurologist involvement with care is associated with greater unadjusted allowed payments, but fewer adverse events and less acute care utilization.
Source: Neurology - January 25, 2016 Category: Neurology Authors: Ney, J. P., Johnson, B., Knabel, T., Craft, K., Kaufman, J. Tags: Cost effectiveness/economic, Outcome research, Medical care, Billing, Insurance ARTICLE Source Type: research

HRS 2016 roundup: Leadless pacers at the fore
Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ), aiming to distinguish their respective leadless pacemaker offerings, presented new data last week in San Francisco at the Heart Rhythm Society’s annual meeting. St. Jude said a subset of data from the Leadless II trial showed that its Nanostim device was was successfully retrieved in 14 patients up to 3.2 years after implantation, with no serious adverse events. “We’ve now shown that for patients requiring device upgrades or new leadless pacing options, late retrievability – even up to 3 years – is possible with the Nanostim leadless pacemak...
Source: Mass Device - May 9, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Boston Scientific Cardiac Rhythm Management HRS 2016 Medtronic St. Jude Medical Source Type: news

Long-Term Persistence of Newly Initiated Warfarin Therapy in Chinese Patients With Nonvalvular Atrial Fibrillation Original Articles
Conclusions— Nonpersistence of warfarin treatment becomes a serious problem for stroke prevention in Chinese patients with nonvalvular AF. Our findings can be used to identify patients who require closer attention or to develop better management strategy for oral anticoagulation therapy.
Source: Circulation: Cardiovascular Quality and Outcomes - July 18, 2016 Category: Cardiology Authors: Wang, Z.-Z., Du, X., Wang, W., Tang, R.-B., Luo, J.-G., Li, C., Chang, S.-S., Liu, X.-H., Sang, C.-H., Yu, R.-H., Long, D.-Y., Wu, J.-H., Bai, R., Liu, N., Ruan, Y.-F., Dong, J.-Z., Ma, C.-S. Tags: Atrial Fibrillation, Compliance/Adherence, Treatment Original Articles Source Type: research

Abstract 072: Impact of Chronic Diabetes on Periprocedural Outcomes Among Patient With Atrial Fibrillation and Flutter Who Underwent Radiofrequency Catheter Ablation Therapy (RFA). Report From the NIS 2014. Session Title: Poster Session I
Conclusions: RFA has a similar procedural safety in diabetics when compared to non-diabetic patients. It remains a safe procedure in diabetics with drug-refractory atrial fibrillation and flutter. Renal failure, CHF, type of Insurance, hospital location and teaching status are predictors of complications after RFA.
Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Alliu, S. E., Adejumo, A., Durojaiye, M., Emmanuel, A., Wolf, L., Lichstein, E., Hecht, M., Stephan, K., Adegbala, O., Onyeakusi, N., Ajayi, T. Tags: Session Title: Poster Session I Source Type: research

Association between Demographic Characteristics and Hospital Admission in Patients Presenting to the Emergency Department for Transient Neurological Attack (P6.277)
Conclusions:Among patients presenting to the ED with TNA, female sex and race are associated with decreased odds of admission, even after adjusting for socioeconomic and vascular risk factors. Further studies are warranted to determine the public health impact of our results.Disclosure: Dr. Kummer has nothing to disclose. Dr. Parikh has nothing to disclose. Dr. Merkler has nothing to disclose. Dr. Kamel has received personal compensation for activities with Genentech as a speaker. Dr. Kamel has received personal compensation in an editorial capacity for Journal Watch Neurology.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Kummer, B., Parikh, N., Merkler, A., Kamel, H. Tags: Cerebrovascular Disease Health Services Research Source Type: research

Old and new oral anticoagulants in the management of atrial fibrillation. Hungarian data.
CONCLUSIONS: We need more effort to improve the effective and high adherence oral anticoagulant therapy in our country. Orv Hetil. 2017; 158(39): 1545-1549. PMID: 28942666 [PubMed - in process]
Source: Orvosi Hetilap - September 26, 2017 Category: General Medicine Authors: Tomcsányi J, Salfer B, Nagy B Tags: Orv Hetil Source Type: research

Making AI Matter in Healthcare
Healthcare is just as prone to fall victim to hype and irrational exuberance as any other complex industry. And the more revolutionary the promise, the more outrageous the overstatements could be. Artificial intelligence has certainly been one of those "next big things" for some time in healthcare. Whether branded as "big data and analytics" or "automated clinical decision support," the results of technology-assisted care, especially in non-clinical and non-emergent settings, have been uneven at best. But a new report indicates AI's time in healthcare is nigh, and technology and policy pioneers are doing their best to ensu...
Source: MDDI - March 9, 2018 Category: Medical Devices Authors: Greg Goth Tags: Software Digital Health Source Type: news

Long term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study.
CONCLUSIONS: This prospective cohort study confirms the low incidence of stroke, major bleeding and intracranial bleeding, and a 76% persistence with treatment, in NVAF patients treated with dabigatran over about two years. PMID: 30260252 [PubMed - as supplied by publisher]
Source: Expert Opinion on Drug Safety - September 29, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Hypertrophic Cardiomyopathy: A Nationwide Cohort Study.
CONCLUSIONS: Compared with warfarin, patients with HCM and AF on NOACs had similar stroke and major bleeding risks, but lower all-cause mortality and composite fatal cardiovascular events. Our data suggest that patients with HCM and AF can be safely and effectively treated with NOACs. PMID: 30472021 [PubMed - as supplied by publisher]
Source: Chest - November 22, 2018 Category: Respiratory Medicine Authors: Jung H, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B, Lip GYH Tags: Chest Source Type: research

Effect of atrial fibrillation in Asian patients undergoing percutaneous coronary intervention with drug-eluting stents for stable coronary artery disease: Results from a Korean nationwide study
Although the prevalence of atrial fibrillation (AF) and percutaneous coronary intervention (PCI) are increasing in Asia, there is a paucity of data concerning the effect of AF in Asian patients undergoing PCI with drug-eluting stents (DESs). Furthermore, the majority of previous studies investigating the effect of AF on prognosis following PCI have exclusively evaluated patients with myocardial infarction (MI). We aimed to evaluate the effect of AF on clinical outcomes of Asian patients undergoing PCI with DES for coronary artery disease (CAD) excluding acute MI. From national health insurance claims data in South Korea, ...
Source: Medicine - November 1, 2018 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research